The proposed mechanism involves melatonin's action on hypothalamic GHRH neurons and its mild somatostatin-suppressive effect
Participants were assigned to receive weekly doses of retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks, or placebo
Discontinuation due to side effects ranged from about 5.3% to 10.3% across the orforglipron doses, against 2.7% on placebo
He told MNT that he hopes these findings dont dampen enthusiasm for the broader line of inquiry. In particular, he told us that he is encouraged by the potential of GLP-1 agonists when combined with lifestyle modification as a preventive strategy to reduce dementia risk before symptoms emerge, where the biology may be far more modifiable. Although the Evoke studies, on paper, failed, there is still hope
This is part of normal metabolic protection and can happen with or without medication
What are the signs that amlodipine and an NSAID are interacting